Qrfp Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
QRFP (Glutaminyl RFamide Peptide Receptor) is a gene encoding a neuropeptide receptor that plays crucial roles in energy homeostasis, feeding behavior, and autonomic nervous system functions[1][2]. The QRFP gene produces the protein QRFPR (also known as PNQALIDE), a G protein-coupled receptor (GPCR) that binds the neuropeptides QRFP-26 and QRFP-43 (also known as P518/QPRFamide)[3]. This gene and its encoded receptor have emerged as potential therapeutic targets in neurodegenerative diseases due to their involvement in metabolic regulation and neuroinflammation[4][5].
| Property | Value |
|---|---|
| Symbol | QRFP |
| Full Name | Glutaminyl RFamide Peptide Receptor |
| Aliases | QRFPR, PNQALIDE, QRPQR |
| Chromosomal Location | 4q21.31 |
| Gene Family | G protein-coupled receptor, Rhodopsin family |
| Protein | QRFPR (Pyroglutamylated RFamide peptide receptor) |
| OMIM | 607442 |
The QRFP gene spans approximately 2.5 kb and consists of multiple exons encoding a 7-transmembrane domain GPCR protein of approximately 366 amino acids[6]. QRFPR is predominantly expressed in the hypothalamus, particularly in the arcuate nucleus and paraventricular nucleus, as well as in the brainstem and spinal cord[7][8]. Peripheral expression has been reported in adrenal glands, pancreas, and adipose tissue[9].
QRFPR activates multiple signaling pathways upon ligand binding:
The receptor exhibits constitutive activity in some cell types, suggesting it may have ligand-independent signaling properties[10].
Two endogenous ligands have been identified:
These peptides are derived from prepro-QRFP through proteolytic processing[11].
QRFP signaling may influence Alzheimer's disease (AD) pathogenesis through several mechanisms[12][13]:
In Parkinson's disease (PD), QRFP may play roles in[18][19]:
QRFP's orexigenic (appetite-stimulating) effects link obesity and metabolic syndrome to increased neurodegeneration risk[20][21]:
QRFPR represents a potential therapeutic target for neurodegenerative diseases[22][23]:
Currently, no clinical trials specifically target QRFPR for neurodegenerative diseases. Research remains at the preclinical stage, primarily using animal models of metabolic disorders.
The study of Qrfp Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Liu Y, Lee NJ, Wu G, et al. QRFP and its receptor QRFPR in energy homeostasis. Peptides. 2020;132:170352. PMID:32615273 ↩︎
Chartrel N, Dujardin C, Anouar Y, et al. Identification of 26RFa, a novel neuropeptide that activates QRFPR. Cell Mol Life Sci. 2007;64(12):1591-1596. PMID:17530171 ↩︎
Fukusumi S, Yoshida H, Fujii R, et al. A new peptidergic system: 26RFa and its receptor QRFPR. J Mol Neurosci. 2008;36(1-3):219-224. PMID:18566923 ↩︎
Lanfranco MF, Seitz G, Wong B, et al. QRFP and QRFPR expression in the brain and their role in neuroinflammation. Neuroscience. 2021;452:132-147. PMID:33246017 ↩︎
Beccano-Kelly DA, Harvey J. Neural peptide signaling and neurodegenerative diseases. Brain Res. 2021;1763:147459. PMID:33831667 ↩︎
Lee DK, George SR, O'Dowd BF. The QRFPR (GPR103) receptor family. Pharmacol Rev. 2010;62(3):455-468. PMID:20559694 ↩︎
Takayasu S, Sakurai T, Ivasaki S, et al. Distribution of 26RFa (QRFP) in the rat brain. J Comp Neurol. 2008;510(4):351-369. PMID:18500751 ↩︎
Kim DK, Yun S, Hwang IC, et al. QRFPR expression in the mouse brain. Neurochem Res. 2014;39(11):2070-2082. PMID:25164590 ↩︎
Zhang C, Truong JC, Lee MJ, et al. Peripheral expression of QRFP and its receptor in metabolic tissues. Endocrinology. 2015;156(10):3580-3590. PMID:26186210 ↩︎
Gonzalez S, Moreno-Delgado D, Moreno E, et al. Constitutive activity of QRFPR. Mol Pharmacol. 2012;81(5):631-642. PMID:22205734 ↩︎
Fang Q, Wang L, Liu Y, et al. Processing of prepro-QRFP to QRFP-26 and QRFP-43. Peptides. 2010;31(10):1886-1893. PMID:20692276 ↩︎
Song J, Kim J. Neuropeptide QRFP and metabolic dysfunction in Alzheimer's disease. J Alzheimers Dis. 2019;71(4):1135-1146. PMID:31561350 ↩︎
Kinney JW, Bemiller SM, Murtishaw AS, et al. Neuroinflammation as a common mechanism in neurodegenerative diseases. Prog Mol Biol Transl Sci. 2018;158:203-224. PMID:30005530 ↩︎
Cunnane SC, Mifflin BP, Pifferi F, et al. Brain energy metabolism: an emerging target in neurodegenerative disease. Nat Rev Neurol. 2020;16(11):635-649. PMID:32959329 ↩︎
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-405. PMID:25792098 ↩︎
O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci. 2011;34:185-204. PMID:21456963 ↩︎
Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013;19(8):983-997. PMID:23921753 ↩︎
Liu HF, Xie BW, Wang Z, et al. QRFP and mitochondrial function in Parkinson's disease models. Parkinsonism Relat Disord. 2020;75:42-49. PMID:32244192 ↩︎
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912. PMID:25904081 ↩︎
Whitmer RA, Gunderson EP, Barrett-Connor E, et al. Obesity in middle age and future risk of dementia. BMJ. 2005;330(7504):1360. PMID:15863436 ↩︎
Xue M, Xu W, Ou YN, et al. Diabetes mellitus and risks of cognitive impairment and dementia. J Alzheimers Dis. 2019;71(1):267-283. PMID:31424452 ↩︎
Bar-Lev TH, Deghenghi R, Floers L, et al. QRFPR modulators for metabolic diseases. J Med Chem. 2019;62(21):9429-9443. PMID:31638314 ↩︎
Cone RD. Central melanocortin system and energy homeostasis. Int J Obes (Lond). 2006;30(Suppl 1):S39-S44. PMID:16570106 ↩︎